Conflicts of interest in psychiatry: Strategies to cultivate literacy in daily practice

Psychiatry and Clinical Neurosciences

Volumn 68, Issue 7, 2014, Pages 489-497

  Shimazawa, Rumiko ^a   Ikeda, Masayuki ^b  

^a OSAKA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

conflict of interest; drug industry; mass media; professional ethics; psychiatry

Indexed keywords

CLINICAL PRACTICE; CLINICAL RESEARCH; CONFLICT OF INTEREST; CONSENSUS; DRUG INDUSTRY; HEALTH CARE POLICY; HEALTH PRACTITIONER; HUMAN; JAPAN; MEDICAL EDUCATION; MEDICAL PRACTICE; PRACTICE GUIDELINE; PSYCHIATRIST; PSYCHIATRY; PUBLIC RELATIONS; PUBLISHING; REVIEW; ETHICS; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DISCLOSURE; HUMANS; PSYCHIATRY;

EID: 84903904152     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12201     Document Type: Review

References (73)

1. Steinbrook R,. Controlling conflict of interest: proposals from the Institute of Medicine. N. Engl. J. Med. 2009; 360: 2160-2163.
2. Thompson DF,. Understanding financial conflicts of interest. N. Engl. J. Med. 1993; 329: 573-576.
3. Maj M,. Non-financial conflicts of interests in psychiatric research and practice. Br. J. Psychiatry 2008; 193: 91-92.
4. Maj M,. Financial and non-financial conflicts of interests in psychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2010; 260: S147-S151.
5. Vanchieri C,. Preparing for thalidomide's comeback. Ann. Intern. Med. 1997; 127: 951-952.
6. Resnik D,. Conflicts of interest in science. Perspect. Sci. 1998; 6: 381-408.
7. Kaliski S,. Conflict of interest: the elephant in your practice. Afr. J. Psychiatry (Johannesbg) 2013; 16: 161-165.
8. Phillips ML, Kupfer DJ,. Bipolar disorder diagnosis: challenges and future directions. Lancet 2013; 381: 1663-1671.
9. Kuehn BM,. APA targets unnecessary antipsychotic use. JAMA 2013; 310: 1909-1910.
10. Lopez OL, Becker JT, Chang YF, etal. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am. J. Psychiatry 2013; 170: 1051-1058.
11. Carpenter WT Jr, Gold JM, Lahti AC, etal. Decisional capacity for informed consent in schizophrenia research. Arch. Gen. Psychiatry 2000; 57: 533-538.
12. Kim SY, Caine ED, Currier GW, Leibovici A, Ryan JM,. Assessing the competence of persons with Alzheimer's disease in providing informed consent for participation in research. Am. J. Psychiatry 2001; 158: 712-717.
13. Kim SY,. Evidence-based ethics for neurology and psychiatry research. NeuroRx 2004; 1: 372-377.
14. Angell M,. The Truth about the Drug Companies. Random House, New York, 2004.
15. Harris G,. Top psychiatrist didn't report drug makers' pay. The New York Times, 3 October 2008. [Cited 8 January 2014.] Available from URL: http://www.nytimes.com/2008/10/04/health/policy/04drug.html?pagewanted= all&-r=0.
16. Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R,. Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: An observational study. BMC Med. Ethics 2012; 13: 24.
17. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA,. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am. J. Psychiatry 2005; 162: 1957-1960.
18. Tanne JH,. US university psychiatrist loses chairmanship over drug company payments. BMJ 2009; 338: a3188.
19. Thacker P,. How an ethically challenged researcher found a home at the University of Miami. Forbes, 13 September 2011. [Cited 8 January 2014.] Available from URL: http://www.forbes.com/sites/paulthacker/2011/09/13/how-an- ethically-challenged-researcher-found-a-home-at-the-university-of-miami/.
20. Wadman M,. Senate watchdog questions US grant to controversial psychiatrist. Nature News Blog, 29 May 2012. [Cited 8 January 2014.] Available from URL: http://blogs.nature.com/news/2012/05/senate-watchdog-questions-nih- award-to-controversial-psychiatrist.html.
21. Harper PS,. Naming of syndromes and unethical activities: The case of Hallervorden and Spatz. Lancet 1996; 348: 1224-1225.
22. Strous RD, Edelman MC,. Eponyms and the Nazi era: Time to remember and time for change. Isr. Med. Assoc. J. 2007; 9: 207-214.
23. Goldstein M,. Decade of the brain. An agenda for the nineties. West. J. Med. 1994; 161: 239-241.
24. Fisher CE, Chin L, Klitzman R,. Defining neuromarketing: Practices and professional challenges. Harv. Rev. Psychiatry 2010; 18: 230-237.
25. Wade N,. A decade later, genetic map yields few new cures. The New York Times, 12 June 2010. [Cited 8 January 2014.] Available from URL: http://www.nytimes.com/2010/06/13/health/research/13genome.html?pagewanted=all
26. Lynch HF,. The rights and wrongs of intentional exposure research: Contextualising the Guatemala STD inoculation study. J. Med. Ethics 2012; 38: 513-515.
27. Reverby SM,. Listening to narratives from the Tuskegee syphilis study. Lancet 2011; 377: 1646-1647.
28. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL,. Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928.
29. Helmchen H,. Ethics of clinical research with mentally ill persons. Eur. Arch. Psychiatry Clin. Neurosci. 2012; 262: 441-452.
30. Wise J,. Pfizer accused of testing new drug without ethical approval. BMJ 2001; 322: 194.
31. World Medical Association. Declaration of Helsinki 2013. [Cited 8 January 2014.] Available from URL: http://www.wma.net/en/30publications/10policies/b3.
32. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S,. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 2006; 163: 185-194.
33. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT,. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008; 5: e45.
34. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R,. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 2008; 358: 252-260.
35. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E,. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 2004; 363: 1341-1345.
36. Penn E, Tracy DK,. The drugs don't work? Antidepressants and the current and future pharmacological management of depression. Ther. Adv. Psychopharmacol. 2012; 2: 179-188.
37. Khan A, Leventhal RM, Khan SR, Brown WA,. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 2002; 22: 40-45.
38. Fournier JC, DeRubeis RJ, Hollon SD, etal. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010; 303: 47-53.
39. Caplan RM,. History of the Society of Medical College Directors of Continuing Medical Education (SMCDCME): The first twelve years, 1976-1988. J. Contin. Educ. Health Prof. 1996; 16: 14-24.
40. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. National Academies Press, Washington, DC [Cited 8 January 2014.] Available from URL: http://books.nap.edu/openbook.php?record-id= 12598.
41. Brennan TA, Rothman DJ, Blank L, etal. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA 2006; 295: 429-433.
42. Geppert CM,. Medical education and the pharmaceutical industry: A review of ethical guidelines and their implications for psychiatric training. Acad. Psychiatry 2007; 31: 32-39.
43. Moynihan R,. Drug company sponsorship of education could be replaced at a fraction of its cost. BMJ 2003; 326: 1163.
44. Stotland N,. APA responds to Sen. Grassley. Psychiatric News 43: 3 5 September 2008. [Cited 8 January 2014.] Available from URL: http://psychnews. psychiatryonline.org/newsarticle.aspx?articleid=112023&RelatedNewsArticles= true.
45. Wazana A,. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000; 283: 373-380.
46. Rothman DJ, McDonald WJ, Berkowitz CD, etal. Professional medical associations and their relationships with industry: A proposal for controlling conflict of interest. JAMA 2009; 301: 1367-1372.
47. Association of American Medical Colleges. Industry funding of medical education. Report of an AAMC Task Force. [Cited 8 January 2014.] Available from URL: https://members.aamc.org/eweb/upload/ Industry%20Funding%20of%20Medical%20Education.pdf.
48. Campbell EG, Weissman JS, Ehringhaus S, etal. Institutional academic industry relationships. JAMA 2007; 298: 1779-1786.
49. Varley CK, Jibson MD, McCarthy M, Benjamin S,. A survey of the interactions between psychiatry residency programs and the pharmaceutical industry. Acad. Psychiatry 2005; 29: 40-46.
50. Brody H,. Pens and other pharmaceutical industry gifts. Am. J. Bioeth. 2003; 3: 58-60.
51. Katz D, Caplan AL, Merz JF,. All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. Am. J. Bioeth. 2003; 3: 39-46.
52. Dana J, Loewenstein G,. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 252-255.
53. Chren MM, Landefeld CS,. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684-689.
54. Sniderman AD, Furberg CD,. Why guideline-making requires reform. JAMA 2009; 301: 429-431.
55. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L,. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother. Psychosom. 2006; 75: 154-160.
56. Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J,. Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychother. Psychosom. 2009; 78: 228-232.
57. Seale C,. Health and media: An overview. Sociol. Health Illn. 2003; 25: 513-531.
58. Wilson A, Bonevski B, Jones A, Henry D,. Media reporting of health interventions: Signs of improvement, but major problems persist. PLoS ONE 2009; 4: e4831.
59. Grilli R, Ramsay C, Minozzi S,. Mass media interventions: Effects on health services utilisation. Cochrane Database Syst. Rev. 2002; (1) CD000389.
60. Jordens CF, Lipworth WL, Kerridge IH,. The quality of Australian health journalism is important for public health. Med. J. Aust. 2013; 199: 448-449.
61. Spielmans GI, Parry PI,. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. Bioeth. Inq. 2010; 7: 13-29.
62. Ferner RE, McDowell SE,. How NICE may be outflanked. BMJ 2006; 332: 1268-1271.
63. Schwartz LM, Woloshin S, Moynihan R,. Who's watching the watchdogs? BMJ 2008; 337: a2535.
64. Burton B, Rowell A,. Unhealthy spin. BMJ 2003; 326: 1205-1207.
65. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV,. High reprint orders in medical journals and pharmaceutical industry funding: Case-control study. BMJ 2012; 344: e4212.
66. Greene JA,. Pharmaceutical marketing research and the prescribing physician. Ann. Intern. Med. 2007; 146: 742-748.
67. Wilkes MS, Doblin BH, Shapiro MF,. Pharmaceutical advertisements in leading medical journals: Experts' assessments. Ann. Intern. Med. 1992; 116: 912-919.
68. Smith R,. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005; 2: e138.
69. Oshima I, Mino Y, Inomata Y,. Institutionalisation and schizophrenia in Japan: Social environments and negative symptoms: Nationwide survey of in-patients. Br. J. Psychiatry 2003; 183: 50-56.
70. Vickery K,. Widening the psychiatric gaze: Reflections on PsychoDoctor, depression, and recent transitions in Japanese mental health care. Transcult. Psychiatry 2010; 47: 363-391.
71. The Economist. Health care in Japan. Regenerative medicine. 23 February 2013. [Cited 8 January 2014.] Available from URL: http://www.economist.com/node/ 21572235.
72. Mahony C,. Second study on valsartan is threatened with retraction over alleged data manipulation. BMJ 2013; 347: f4920.
73. Senba J,. [Conflict of interest viewed from over-seas reports regarding relationship between clinical psychiatry and drug industry]. Seishin Shinkeigaku Zasshi 2010; 112: 1124-1129.